Results 211 to 220 of about 10,168 (235)

Initial development of biosimilar immune checkpoint blockers using HEK293 cells

Protein Expression and Purification, 2020
Antibodies that block interaction of immune checkpoint receptors with its ligands have revolutionized the treatment of several cancers. Despite the success of this approach, the high cost has been restricted the use of this class of drugs. In this context, the development of biosimilar can be an important strategy for reducing prices and expanding ...
Michael Bernardes, Ramos, Anna Erika Vieira de, Araújo, Cristiane Pinheiro, Pestana, Ana Paula Dinis, Ano Bom, Renata Chagas, Bastos, Aline, de Almeida Oliveira, Patrícia Cristina, da Costa Neves, Haroldo Cid, da Silva Junior   +7 more
openaire   +2 more sources

Losartan controls immune checkpoint blocker-induced edema and improves survival in glioblastoma

2022
AbstractImmune checkpoint blockers (ICBs) have failed in all Phase III glioblastoma trials. Here, we found that ICBs induce cerebral edema in some patients and mice with glioblastoma. Through single-cell RNA sequencing, intravital imaging, and T cell blocking studies in mice, we demonstrated that this edema results from an inflammatory response ...
Meenal Datta, Sampurna Chatterjee, Elizabeth M. Perez, Simon Gritsch, Sylvie Roberge, Mark Duquette, Ivy X. Chen, Kamila Naxerova, Ashwin S. Kumar, Mitrajit Ghosh, Kyrre E. Emblem, Mei R. Ng, William W. Ho, Pragya Kumar, Shanmugarajan Krishnan, Xinyue Dong, Maria C. Speranza, Martha R. Neagu, David A. Reardon, Arlene H. Sharpe, Gordon J. Freeman, Mario L. Suvà, Lei Xu, Rakesh K. Jain   +23 more
openaire   +1 more source

Impact of Immunosuppressive Agents on the Management of Immune-Related Adverse Events of Immune Checkpoint Blockers

European Journal of Cancer
Immune checkpoint blockers (ICBs) can induce immune-related adverse events (irAEs) whose management is based on expert opinion and may require the prescription of steroids and/or immunosuppressants (ISs). Recent data suggest that these treatments can reduce the effectiveness of ICBs.To investigate the relationship between the use of steroids and/or ISs
Pierre-Louis, Cariou, Cédric, Pobel, Jean-Marie, Michot, François-Xavier, Danlos, Benjamin, Besse, Franck, Carbonnel, Xavier, Mariette, Aurélien, Marabelle, Sabine, Messayke, Caroline, Robert, Emilie, Routier, Nicolas, Noël, Olivier, Lambotte   +12 more
openaire   +2 more sources

Dupilumab for the treatment of immune checkpoint blockers' induced pruritus

Journal of the European Academy of Dermatology and Venereology, 2023
Evdoxia Panou, Flora Stavridi, Christos Nikolaou, Alexander Stratigos, Vasiliki Nikolaou   +4 more
openaire   +2 more sources

Clinical toxicology of immune checkpoint blockers

Toxicology Letters, 2021
openaire   +1 more source

Methotrexate in the treatment of immune checkpoint blocker-induced bullous pemphigoid

European Journal of Cancer, 2021
Connie R, Shi, Tracey S, Otto, Leah L, Thompson, Michael S, Chang, Kerry L, Reynolds, Steven T, Chen   +5 more
openaire   +2 more sources

An interdisciplinary consensus on the management of brain metastases in patients with renal cell carcinoma

Ca-A Cancer Journal for Clinicians, 2022
Elshad Hasanov, Marion Smits, Priscilla K Brastianos   +2 more
exaly  

Analysis of the association between prospectively collected immune-related adverse events and survival in patients with solid tumor treated with immune-checkpoint blockers, taking into account immortal-time bias

Cancer Treatment Reviews, 2022
Maria Kfoury
exaly  

A review of cancer immunotherapy toxicity

Ca-A Cancer Journal for Clinicians, 2020
Lucy Boyce Kennedy
exaly  

Cytotoxic T Cells Are Replaced by Novel Clones After Immune Checkpoint Blocker Therapy

Journal of Cutaneous Medicine and Surgery, 2020
Pingxing Xie, Philippe Lefraçnois, Ivan V. Litvinov   +2 more
openaire   +2 more sources